Clinical trials: Plasmodium Falciparum Malaria
Plasmodium Falciparum Infection
Adenovirus Vaccine for Malaria
Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine licensed to prevent malaria. The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the…
- Trial name
- NCT00371189
- Testing
- Ad35.CS.01 Circumsporozoite Malaria Vaccine
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention
In areas of the Sahel sub-region of Africa with intense seasonal malaria transmission, seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SP+AQ) has become the standard-of-care for the…
- Trial name
- DRUMARS (NCT04969185)
- Where
- 2 sites in Burkina Faso
- Volunteers
- 310 people
- Sponsor
- University of California, San Francisco
Uncomplicated Malaria
Malaria Therapeutic Efficacy Study (TES) Kenya
WHO recommends that Therapeutic Efficacy Studies (TES) for 1st and 2nd line antimalarial medicines should be routinely carried out and data made available for decision-making due to the threat of emergence and spread of…
- Trial name
- Kenya-TES (NCT04767191)
- Testing
- artemether lumefantrine, dihydroartemisinin piperaquine
- Where
- 2 sites in Kenya
- Volunteers
- 400 people
- Sponsor
- Jhpiego
Malaria, Falciparum
A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™
The Study was designed to evaluate the pharmacokinetics of DHA and PQ in healthy volunteers and to assess the effect of ethnicity (Asian vs Caucasian), gender and body weight on the relative bioavailability of DHA and PQ.
- Trial name
- NCT01222949
- Testing
- Eurartesim
- Where
- 2 sites in Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- sigma-tau i.f.r. S.p.A.
Malaria
PALUREA: Severe Imported Malaria in Adults
Plasmodium falciparum malaria remains a major public health problem in endemic areas, with approximately 2 million deaths each year, especially in tropical African countries.
- Trial name
- PALUREA (NCT00372684)
- Testing
- with severe malaria hospitalized in ICU, with uncomplicated malaria
- Where
- France
- Volunteers
- 302 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Plasmodium Falciparum Malaria
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
- Trial name
- NCT00312663
- Testing
- Falciparum Malaria Protein 11 with AS01B adjuvant.
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria,Falciparum
Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali
The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artemether-lumefantrine (AL) with and without a single dose of 0.25mg/kg primaquine (PQ) and sulfadoxine-pyrimethamine with…
- Trial name
- NECTAR3 (NCT05081089)
- Testing
- Artemether-lumefantrine, Primaquine Phosphate, Sulphadoxine-pyrimethamine with amodiaquine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Falciparum Malaria
Biological Mechanisms in Afebrile P. Falciparum Malaria
This project aims to disentangle the role of host immune resistance and disease tolerance in afebrile malaria infections, with the goal of guiding context-adapted tactics to target this hidden reservoir, as well as to develop new…
- Trial name
- AsintMal (NCT04422015)
- Testing
- No intervention
- Where
- Mozambique
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Alfredo Mayor
Malaria, Falciparum
MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
A single-centre, open-label, study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection.
- Trial name
- NCT02281344
- Testing
- MMV390048 20mg
- Where
- Australia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Uncomplicated Plasmodium Falciparum Malaria
Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity
This is a two-arm, open label Treatment Study comparing the efficacy, safety, tolerability and pharmacokinetics of a three-day course of Dihydroartemisinin-Piperaquine (DP) with or without single-dose primaquine in patients with…
- Trial name
- NCT01849640
- Testing
- DHA-piperaquine and Primaquine
- Where
- Cambodia
- Volunteers
- 150 people
- Sponsor
- David Saunders
Malaria
Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
This Phase I study will evaluate the safety, tolerability and pharmacokinetic properties of escalating single doses of reformulated MMV390048 when administered to healthy men and women of non-childbearing potential (WNCBP) under…
- Trial name
- NCT02783820
- Testing
- MMV390048 40 mg, MMV390048 80 mg, MMV390048 120 mg
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria
No pediatric formulations of quinine exist. Therefore, quinine tablets are broken into 2 or 4 parts, according to the body weight. Based on the body weight, 1/2 or 1/4 a tablet is administered to the child.
- Trial name
- NCT00329134
- Testing
- Administration of quinine sulphate taste-masked pellets
- Where
- Rwanda
- Volunteers
- 56 people
- Sponsor
- University Ghent
Malaria,Falciparum, Malaria Recrudescence
TES of Artemether-lumefantrine for Pf in the Philippines in 2015
Artemether-lumefantrine has been used as a first-line treatment for uncomplicated Plasmodium falciparum infection since 2009 in the Philippines.
- Trial name
- TES (NCT05958693)
- Testing
- Artemether-lumefantrine, Primaquine
- Volunteers
- 82 people
- Sponsor
- Research Institute for Tropical Medicine, Philippines
Malaria
Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains
An effective vaccine against malaria is urgently needed to combat the scourge of this disease. Before candidate vaccines can be tested in endemic countries, they are first tested in human volunteers in so-called Controlled Human…
- Trial name
- NCT02149550
- Testing
- NF135 n=5, NF135 n=2, NF135 n=1
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children
This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 5 sites of the two oral ACTS…
- Trial name
- MEFI (NCT02168569)
- Testing
- Coartem™ (Artemether-lumefantrine combination), Coarsucam™ (Amodiaquine-artesunate combination)
- Where
- 5 sites in Mozambique
- Volunteers
- 700 people
- Sponsor
- Centro de Investigacao em Saude de Manhica
Plasmodium Falciparum
Plasmodium Falciparum Artemisinin Resistance Vietnam
Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the successful treatment of malaria, has been confirmed in Cambodia.
- Trial name
- NCT01775592
- Testing
- Arterakin (DHA-PPQ)
- Where
- Vietnam
- Volunteers
- 95 people
- Sponsor
- National Institute of Malariology, Parasitology and Entomology, Vietnam
Malaria
Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil
This is an in vivo evaluation of drug efficacy performed in Cruzeiro do Sul, in the state of Acre, Brazil. A total of 81 participants ≥5 years old with parasitological confirmation of P.
- Trial name
- NCT02600767
- Testing
- Artemether-lumefantrine combination
- Where
- Brazil
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Plasmodium Falciparum Malaria
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study was to evaluate PK, safety, tolerability and efficacy of a new formulation of artemether-lumefantrine dispersible tablet in neonates and infants <5 kg body weight with acute uncomplicated Plasmodium…
- Trial name
- CALINA (NCT04300309)
- Testing
- artemether:lumefantrine (2.5 mg:30 mg)
- Where
- 3 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Falciparum, Malaria
Sporozoite Challenge of Polyprotein Vaccinees
This study examines the ability of two new malaria vaccines (FP9-PP and MVA-PP) to prevent the development of malaria infection after controlled exposure to the parasite.
- Trial name
- NCT00375128
- Testing
- FP9-PP (FP9 polyprotein), MVA-PP (Modified Virus Ankara polyprotein)
- Where
- 2 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Malaria,Falciparum
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso
- Trial name
- NCT05790889
- Testing
- Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Oxford